DIVISION	<u>of Health Service Re</u>								
STATEMENT OF DEFICIENCIES (X1) PI		(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION A. BUILDING:		(X3) DATE SURVEY COMPLETED				
MHL092-338		B. WING		04/10/2018					
NAME OF F	PROVIDER OR SUPPLIER	STREET ADI	DRESS, CITY, S	STATE, ZIP CODE					
-				DOW LANE.					
STMAR	('S MANOR		RINGS, NC						
(VA) ID	SHIMMARY STA	ATEMENT OF DEFICIENCIES	ID	PROVIDER'S PLAN OF CORRECT	ON (ve)				
(X4) ID PREFIX TAG	(EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)		PREFIX TAG	(EACH CORRECTIVE ACTION SHOU CROSS-REFERENCED TO THE APPRO DEFICIENCY)	D BE COMPLETE				
∨ 000	INITIAL COMMENTS		V 000						
	An annual survey v Deficiencies were	vas completed on 4/10/18. cited.							
	category: 10A NCA	sed for the following service C 27G 5600C Supervised							
	Living for Adults Wi	th Developmental Disabilities.							
V 118	27G .0209 (C) Med	lication Requirements	V 118						
	10A NCAC 27G .02	209 MEDICATION							
	REQUIREMENTS								
to:	(c) Medication adm	nnistration: non-prescription drugs shall							
		ed to a client on the written							
		authorized by law to prescribe							
	drugs.	•							
		all be self-administered by							
		uthorized in writing by the							
	client's physician.	cluding injections, shall be							
		by licensed persons, or by							
		s trained by a registered nurse,							
		r legally qualified person and							
		re and administer medications.		RECEIVED	1				
		dministration Record (MAR) of ered to each client must be kept		ADD 0.0 2010					
	current. Medication	ns administered shall be		APR 2 0 2013					
	MAR is to include to the control of	tely after administration. The the following:		DHSR-MH Licensure	Sect				
1		, and quantity of the drug;							
		administering the drug;							
	(D) date and time t	the drug is administered; and			1				
	` '	of person administering the							
	drug.				4				
		for medication changes or	ļ						
		corded and kept with the MAR appointment or consultation							
	with a physician.	appointment or consumation			,				
Division of H	ealth Service Regulation		<u>, </u>	1					
LABORATORY DISECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE (X6) DATE									
(Trisulle Getter Transfich 4-20-18									
STATE FOR			6899	VEOIM	15				

STATE FORM

YFQI11

4-20-18

Division of Health Service Regulation FORM APPROVE								
STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PRO IDEN		(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION A. BUILDING:		(X3) DATE SURVEY COMPLETED			
		MHL092-338	B. WING	B. WING		04/10/2018		
NAME OF F	NAME OF PROVIDER OR SUPPLIER STREET AD			DRESS, CITY, STATE, ZIP CODE				
STMADE	C'S MANOR			ADOW LANE				
OT MAIN	(3 MANOR		PRINGS, NO					
(X4) ID	SUMMARY STATEMENT OF DEFICIENCIES		ID	PROVIDER'S PLAN OF CORRECTION	7N	1		
PREFIX TAG	(EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)		PREFIX TAG	(EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY) (X5) COMPLE DATE				
V 118	Continued From pa	ge 1	V 118					
	This Rule is not me	et as evidenced by:						
	failed to ensure med on the written order	view and interview the facility dications were administered of a person authorized by law or 2 of 3 audited clients (#1 gs are:						
	 Admission date: Diagnoses: Sev Bipolar, Seizure Dis Autism, Recurrent L and Gall Bladder Di: Physician's orde 	ere Mental Retardation, order, Psychotic Disorder, JTI (Urinary Track Infection)						
THE PARTY OF THE P	10 mg 1 tablet by m	outh at bedtime MAR: No transcription for				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
	Interview on 4/9/18 v	with staff #1 revealed: re client #1 had an order for		In reference to VI The administration	18			
	Cetirizine The medication wasn't sent to the facility by the pharmacy therefore it wasn't administered in January or February							
				Verify with doctor A				
	Interview on 4/10/18 with the Owner revealed:		,	Phermocy that evel med	ucens			
	 There was some client #1's Cetirizine hospital 	discrepancies regarding when she went into the		one Current, indirof in MAR and in th				
	The issue has be client #1 is receiving	een straightened out and the Cetirizine		facility at least of	nce	4-10-18		
	Review on 4/5/18 of Admission date:	client #3's record revealed: 5/2000		a month to rema	U-C			

Division of Health Service Regulation STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION (X3) DATE SURVEY IDENTIFICATION NUMBER: COMPLETED A. BUILDING: MHL092-338 B. WING 04/10/2018 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE 3735 HERITAGE MEADOW LANE ST MARK'S MANOR HOLLY SPRINGS, NC 27540 (X4) ID PREFIX SUMMARY STATEMENT OF DEFICIENCIES PROVIDER'S PLAN OF CORRECTION (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION) (X5) COMPLETE DATE PREFIX (EACH CORRECTIVE ACTION SHOULD BE TAG CROSS-REFERENCED TO THE APPROPRIATE TAG DEFICIENCY) V 118 Continued From page 2 V 118 Diagnoses: Moderate Mental Retardation, Diabetes - Type 2, Hypertension, Asthma, Restrictive Lung Disorder, Blindness, Anxiety and **Decreased Hearing** Physician's order dated 3/6/18: Clonazepam (used to treat Panic and Anxiety Disorder) 1 tablet by mouth twice daily as needed Observation on 4/5/18 at 2:30 pm of client #3's medications revealed: In refrere to VIIS

The orderent will

Check all Pris orderence

They are available in

pite at least once
a month to remain in No evidence of Clonazepam on site Interview on 4/5/18 with staff #1 revealed: Client #3's Clonazepam has been ordered and should be delivered by the pharmacy soon Interview on 4/10/18 with the Owner revealed: He confirmed client #3's Clonazepam had been ordered H-10-18 V 121 27G .0209 (F) Medication Requirements V 121 Complinee. 10A NCAC 27G .0209 MEDICATION REQUIREMENTS (f) Medication review: (1) If the client receives psychotropic drugs, the governing body or operator shall be responsible for obtaining a review of each client's drug regimen at least every six months. The review shall be to be performed by a pharmacist or physician. The on-site manager shall assure that the client's physician is informed of the results of the review when medical intervention is indicated. (2) The findings of the drug regimen review shall be recorded in the client record along with corrective action, if applicable.

Division of Health Service Regulation

Division of Health Service Regulation STATEMENT OF DEFICIENCIES (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION (X3) DATE SURVEY AND PLAN OF CORRECTION **IDENTIFICATION NUMBER:** COMPLETED A. BUILDING: MHL092-338 B. WING 04/10/2018 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE 3735 HERITAGE MEADOW LANE ST MARK'S MANOR HOLLY SPRINGS, NC 27540 SUMMARY STATEMENT OF DEFICIENCIES (X4) ID PREFIX PROVIDER'S PLAN OF CORRECTION ID PREFIX (X5) COMPLETE (EACH DEFICIENCY MUST BE PRECEDED BY FULL (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE REGULATORY OR LSC IDENTIFYING INFORMATION) TAG TAG DATE DEFICIENCY) V 121 Continued From page 3 V 121 This Rule is not met as evidenced by: Based on record review and interview, the facility failed to ensure a drug regimen review was completed at least every 6 months for 3 of 3 clients (#1 - #3). The findings are: Review on 4/9/18 of client #1's record revealed: In reference des VIII Administration will ensure drug reviews One conducted every 6 4/30/18 Admission date: 11/2002 Diagnoses: Severe Mental Retardation, Bipolar, Seizure Disorder, Psychotic Disorder, Autism, Recurrent UTI (Urinary Track Infection) and Gall Bladder Disorder Drug Regimen 9/22/17 - 4/9/18 included: Latuda (used to treat Schizophrenia), Fluoxetine (used to treat Depression, Obsessive Compulsive months as required to Disorder and Panic Disorder) and Lorazepam (used to treat anxiety) removi en complince No evidence of a 6 month drug review Review on 4/5/18 of client #2's record revealed: Admission date: 11/2003 On reference do VIDI Diagnoses: Mild Mental Retardation. Hyperlipidemia, Hypothyroidism and GERD (Gastroesophageal Reflux Disease) Drug Regimen 10/21/16 - 4/5/18 included: Quetiapine (used to treat Schizophrenia, Bipolar and Depression) No evidence of a 6 month drug review Review on 4/5/18 of client #3's record revealed: 6 months to lemcen Admission date: 5/2000 Diagnoses: Moderate Mental Retardation, In refere to VIDI Admirable 4/30/18 Diabetes - Type 2, Hypertension, Asthma. Restrictive Lung Disorder, Blindness, Anxiety and well ensure drug rais **Decreased Hearing** Drug Regimen 3/3/17 - 4/5/18 included are conducted ever to Clonazepam (used to treat Panic Disorder and Mineles as regeried to Anxiety No evidence of a 6 month drug review remain in-Compliance.

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION (X3) DATE SURVEY IDENTIFICATION NUMBER: A. BUILDING: COMPLETED B. WING MHL092-338 04/10/2018 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE 3735 HERITAGE MEADOW LANE ST MARK'S MANOR **HOLLY SPRINGS, NC 27540** (X4) ID PREFIX SUMMARY STATEMENT OF DEFICIENCIES PROVIDER'S PLAN OF CORRECTION ID PREFIX (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION) (X5) COMPLETE DATE (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY) TAG TAG V 121 Continued From page 4 V 121 Interview on 4/5/18 with staff #1 revealed: An referee to VIZI Admendata will Insue draig review is conducted to The facility had recently changed pharmacy's She's contacted the pharmacy and they're going to send someone to complete the drug regimens for all clients Interview on 4/10/18 with the Owner revealed: 4-30-18 He's aware the drug reviews had not been completed They've contacted the pharmacy and someone will be out to the home to complete the drug reviews next week Division of Health Service Regulation

Division of Health Service Regulation